ERBB2 and ductal breast carcinoma in situ: Another notable observation is that while 60% of pure DCIS in one study exhibited evidence of HER2 gene amplification, this dropped to 25% of with infiltrating ductal carcinoma, co-existent with the difference between in situ and invasive being even more marked when high nuclear grade lesions were matched (Barnes et al, 1992).